Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
- 319 Downloads
Purpose of Review
Immune checkpoint therapy has dramatically changed the therapeutic landscape of solid malignancies. Here, we review the scientific rationale and current data evaluating immune checkpoint inhibitors in acute myeloid leukemia (AML).
Immune checkpoint inhibitor monotherapy has shown limited clinical activity in AML. Initial results from early-phase clinical trials suggest that rational combinations of immune checkpoint inhibition with hypomethylating agents (HMAs) are safe and potentially more promising. There are currently no data directly comparing immune checkpoint inhibition to standard therapies. Emerging immune targets more specific for leukemia cells including LILRB4 may improve future therapeutic efficacy.
The success of immune checkpoint inhibition in AML has been modest to date. However, an improved understanding of the biology and the use of rational combinations has potential to improve rates of durable responses. Multiple clinical trials in AML are currently evaluating the use of immune checkpoints alone and in combination.
KeywordsAcute myeloid leukemia Immune checkpoints Immunotherapy Azacitidine Decitabine Pembrolizumab Ipilimumab Nivolumab PD-1 PD-L1 CTLA-4 LILRB4
Compliance with Ethical Standards
Conflict of Interest
Maximilian Stahl declares that he has no conflict of interest.
Aaron D. Goldberg has received research funding from Arog Pharmaceuticals, Pfizer, ADC Therapeutics, the American Society of Clinical Oncology, and the American Society of Hematology; and has received speaker’s honorarium and travel reimbursements from DAVA Oncology and compensation from Abbvie, Celgene, and Daiichi-Sankyo for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Podoltsev NA, Stahl M, Zeidan AM, et al. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43–62. https://doi.org/10.1016/j.blre.2016.09.005.
- 6.Kayser S, Walter RB, Stock W, et al. Minimal residual disease in acute myeloid leukemia-current status and future perspectives. Curr Hematol Malig Rep. 2015;10(2):132–44. https://doi.org/10.1007/s11899-015-0260-7.
- 22.•• Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143–53. This study demonstrates a significant benefit of high-dose ipilimumab in a small subgroup of patients with extramedullary AML relapse after allogeneic stem cell transplant.CrossRefGoogle Scholar
- 25.Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14:3044–51.Google Scholar
- 26.Ravandi FD. Dea: phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. Atlanta: American Society of Hematology 59th Annual Meeeting; 2017. p. 2017.Google Scholar
- 27.Zeidner JV. Bea: phase II study of high dose cytarabine followed by pembrolizumab in relapsed/refractory acute myeloid leukemia (AML). Atlanta: American Society of Hematology 59th Annual Meeeting; 2017.Google Scholar
- 28.•• Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a non-randomized, open-label, phase 2 study. Cancer Discov. 2018. First study showing a favorably response and survival rate with azacitidine and nivolumab in RR-AML patients compared to historical survival with azacitidine monotherapy in a similar patient population. Google Scholar
- 33.• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–8. This study demonstrated that immune checkpoint inhibition is upregulated in response to hypomethylating agents leading to acquired hypomethylating agent resistance. These findings also argue for trials examining the combination of hypomethylating agents with immune checkpoint inhbitors in AML and MDS. CrossRefGoogle Scholar
- 55.Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908–18.CrossRefGoogle Scholar
- 59.Srivastava P, Paluch BE, Matsuzaki J, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016.Google Scholar
- 61.Steinmann J, Bertz H, Wasch R, et al. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant. 2015;50(5):690–5. https://doi.org/10.1038/bmt.2015.10.
- 67.Paola Dama MT, Fulton N, et al. Profiling the immune checkpoint pathway in acute myeloid leukemia: American Society of Clinical Oncology (ASCO) meeting; 2018.Google Scholar
- 69.Versteven M, Van den Bergh JMJ, Marcq E, et al. Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer. Front Immunol. 2018;9:394. https://doi.org/10.3389/fimmu.2018.00394.
- 70.•• Deng M, Gui X, Kim J, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605–9. This paper demonstrated that leukocyte immunoglobulin–like receptor B4 (LILRB4) is a promising new target for immune checkpoint inhibition in monocytic AML. CrossRefGoogle Scholar
- 74.Patrick Williams SB, Garcia-Manero G, et al. Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML: American Society of Clinical Oncology (ASCO) meeting; 2018.Google Scholar
- 76.El Kholy NM, Sallam MM, Ahmed MB, et al. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol. 2011;28(1):270–8. https://doi.org/10.1007/s12032-010-9459-6.